| CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative F Ghiringhelli, N Larmonier, E Schmitt, A Parcellier, D Cathelin, C Garrido, ... European journal of immunology 34 (2), 336-344, 2004 | 1151 | 2004 |
| Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer D Alizadeh, M Trad, NT Hanke, CB Larmonier, N Janikashvili, B Bonnotte, ... Cancer research 74 (1), 104-118, 2014 | 400 | 2014 |
| CD4+ CD25+ FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease X Chen, B Zhou, M Li, Q Deng, X Wu, X Le, C Wu, N Larmonier, W Zhang, ... Clinical immunology 123 (1), 50-59, 2007 | 378 | 2007 |
| Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10 N Larmonier, M Marron, Y Zeng, J Cantrell, A Romanoski, M Sepassi, ... Cancer Immunology, Immunotherapy 56, 48-59, 2007 | 320 | 2007 |
| Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis M Samson, S Audia, J Fraszczak, M Trad, P Ornetti, D Lakomy, M Ciudad, ... Arthritis & Rheumatism 64 (11), 3788-3798, 2012 | 219 | 2012 |
| Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL− tumors N Larmonier, N Janikashvili, CJ LaCasse, CB Larmonier, J Cantrell, ... The Journal of Immunology 181 (10), 6955-6963, 2008 | 188 | 2008 |
| Immune checkpoint inhibitors and elderly people: a review A Daste, C Domblides, M Gross-Goupil, C Chakiba, A Quivy, V Cochin, ... European Journal of Cancer 82, 155-166, 2017 | 186 | 2017 |
| Chemotherapeutic targeting of cancer-induced immunosuppressive cells D Alizadeh, N Larmonier Cancer research 74 (10), 2663-2668, 2014 | 159 | 2014 |
| Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate … S Audia, A Nicolas, D Cathelin, N Larmonier, C Ferrand, P Foucher, ... Clinical & Experimental Immunology 150 (3), 523-530, 2007 | 151 | 2007 |
| Immunologic effects of rituximab on the human spleen in immune thrombocytopenia S Audia, M Samson, J Guy, N Janikashvili, J Fraszczak, M Trad, M Ciudad, ... Blood, The Journal of the American Society of Hematology 118 (16), 4394-4400, 2011 | 134 | 2011 |
| Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease CB Larmonier, MT Midura-Kiela, R Ramalingam, D Laubitz, N Janikashvili, ... Inflammatory bowel diseases 17 (2), 503-515, 2011 | 120 | 2011 |
| Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay X Chen, Q Yang, M Zhang, M Graner, X Zhu, N Larmonier, M Liao, W Yu, ... Clinical and Vaccine Immunology 16 (6), 879-884, 2009 | 111 | 2009 |
| Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells S Gurbuxani, JM Bruey, A Fromentin, N Larmonier, A Parcellier, ... Oncogene 20 (51), 7478-7485, 2001 | 111 | 2001 |
| The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance N Janikashvili, B Bonnotte, E Katsanis, N Larmonier Journal of Immunology Research 2011, 2011 | 104 | 2011 |
| Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system B Bonnotte, N Larmonier, N Favre, A Fromentin, M Moutet, M Martin, ... The Journal of Immunology 167 (9), 5077-5083, 2001 | 101 | 2001 |
| Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25−FoxP3− T cells SM Centuori, M Trad, CJ LaCasse, D Alizadeh, CB Larmonier, NT Hanke, ... Journal of leukocyte biology 92 (5), 987-997, 2012 | 92 | 2012 |
| Polychlorinated biphenyl-induced effects on metabolic enzymes, AP-1 binding, vitamin E, and oxidative stress in the rat liver TP Twaroski, ML O'Brien, N Larmonier, HP Glauert, LW Robertson Toxicology and applied pharmacology 171 (2), 85-93, 2001 | 90 | 2001 |
| Beyond the tumour microenvironment L Laplane, D Duluc, A Bikfalvi, N Larmonier, T Pradeu International journal of cancer 145 (10), 2611-2618, 2019 | 89 | 2019 |
| IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity D Alizadeh, RA Wong, S Gholamin, M Maker, M Aftabizadeh, X Yang, ... Cancer discovery 11 (9), 2248-2265, 2021 | 88 | 2021 |
| Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent C Billerey-Larmonier, JK Uno, N Larmonier, AJ Midura, B Timmermann, ... Inflammatory bowel diseases 14 (6), 780-793, 2008 | 87 | 2008 |
Emmanuel Katsanis, M.D.University of ArizonaVerified email at peds.arizona.edu
